C12N 2799/026
Where the vector is derived from a baculovirus
Official title: where the vector is derived from a baculovirus
C12N2799/026 (Where the vector is derived from a baculovirus) appears on 986 US grants and 1,545 published applications in this corpus.
Search patents in C12N- Granted patents
- 986
- Published applications
- 1,545
- Assignees
- 306
- Inventors
- 1,185
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 4 | 0 |
| 1996 | 10 | 0 |
| 1997 | 27 | 0 |
| 1998 | 52 | 0 |
| 1999 | 58 | 0 |
| 2000 | 56 | 0 |
| 2001 | 41 | 10 |
| 2002 | 67 | 145 |
| 2003 | 53 | 865 |
| 2004 | 48 | 102 |
| 2005 | 48 | 104 |
| 2006 | 69 | 48 |
| 2007 | 137 | 51 |
| 2008 | 120 | 48 |
| 2009 | 48 | 40 |
| 2010 | 34 | 25 |
| 2011 | 27 | 15 |
| 2012 | 18 | 20 |
| 2013 | 11 | 8 |
| 2014 | 7 | 16 |
| 2015 | 7 | 7 |
| 2016 | 10 | 7 |
| 2017 | 8 | 13 |
| 2018 | 10 | 3 |
| 2019 | 0 | 4 |
| 2020 | 3 | 3 |
| 2021 | 2 | 2 |
| 2022 | 1 | 3 |
| 2023 | 0 | 1 |
| 2024 | 1 | 1 |
| 2025 | 4 | 3 |
| 2026 | 2 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Baculovirus expression vector4 Aug 2026US 12,697,381 B2Intervet Inc.
- Hepatitis E virus-like particles (VLPs) derived from consensus sequences19 May 2026US 12,630,844 B2Novo Capsid Technologies LLC
- Further improved AAV vectors produced in insect cells21 Oct 2025US 12,448,628 B2uniQure IP B.V.
- Human monoclonal antibody human CD134 (OX40) and methods of making and using same3 Jun 2025US 12,319,741 B2Kyowa Kirin Co., Ltd.
- Binding domains directed against GPCR:G protein complexes and uses derived thereof18 Mar 2025US 12,252,521 B2The Board of Trustees of the Leland Stanford Junior University
- Further improved aav vectors produced in insect cells23 Jul 2026US 2026/0209798 A1uniQure IP B.V.
- Pcv2 orf2 protein variant and virus like particles composed thereof31 Jul 2025US 2025/0243246 A1Boehringer Ingelheim Animal Health USA Inc.
- Hepatitis e virus-like particles (vlps) derived from consensus sequences24 Jul 2025US 2025/0236885 A1Novo Capsid Technologies LLC
- Binding Domains Directed Against GPCR:G Protein Complexes and Uses Derived Thereof29 May 2025US 2025/0171510 A1The Board of Trustees of the Leland Stanford Junior University
- Pcv2 orf2 protein variant and virus like particles composed thereof7 Mar 2024US 2024/0076321 A1Boehringer Ingelheim Animal Health USA Inc.
Most cited
By later US patents
- Method for generating an animal homozygous for a genetic modification199US 7,294,754 B2Regeneron Pharmaceuticals, Inc. · 2007
- Human TNF receptor126US 5,610,279 AHoffman-La Roche Inc. · 1997
- Sialyiation of N-linked glycoproteins in the baculovirus expression vector system124US 6,261,805 B1Boyce Thompson Institute for Plant Research, Inc. · 2001
- Method for making homozygous genetic modifications111US 7,659,442 B2Regeneron Pharmaceuticals, Inc. · 2010
- Anti-CD40 monoclonal antibodies capable of blocking B-cell activation109US 5,677,165 AChiron Corporation · 1997